Share on StockTwits

Analysts at Feltl & Co. began coverage on shares of Tandem Diabetes Care (NASDAQ:TNDM) in a research report issued to clients and investors on Thursday, reports. The firm set a “strong-buy” rating on the stock.

A number of other firms have also recently commented on TNDM. Analysts at Bank of America upgraded shares of Tandem Diabetes Care from a “neutral” rating to a “buy” rating in a research note on Friday, August 1st. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Tandem Diabetes Care in a research note on Friday, August 1st. They now have a $25.00 price target on the stock. Finally, analysts at William Blair initiated coverage on shares of Tandem Diabetes Care in a research note on Tuesday, July 15th. They set an “outperform” rating and a $2.00 price target on the stock. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $20.75.

Shares of Tandem Diabetes Care (NASDAQ:TNDM) traded up 4.44% on Thursday, hitting $14.34. 64,355 shares of the company’s stock traded hands. Tandem Diabetes Care has a 52 week low of $1.791 and a 52 week high of $30.25. The stock has a 50-day moving average of $13.86 and a 200-day moving average of $17.76. The company’s market cap is $336.5 million.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.08. The company had revenue of $10.26 million for the quarter, compared to the consensus estimate of $10.36 million. The company’s revenue for the quarter was up 85.5% on a year-over-year basis. Analysts expect that Tandem Diabetes Care will post $-3.39 EPS for the current fiscal year.

In other Tandem Diabetes Care news, COO John F. Sheridan sold 2,000 shares of Tandem Diabetes Care stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $13.99, for a total value of $27,980.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Tandem Diabetes Care, Inc is a medical device company with an approach to design, develop and commercialize products for people with insulin-dependent diabetes.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.